Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders

References

• About psoriasis National Psoriasis Foundation [accessed 2009 Sep 15]. Available from: http://www.psoriasis.org/netcommunity/learn01.
   Google Scholar
• Ellerin T, Rubin RH, Weinblatt ME. Infection and anti-tumor necrosis factor α therapy. Arthritis Rheum. 2003;48(11):3013–3022.
   PubMedGoogle Scholar
• Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst. 1988;80(13):1039–1044.
   PubMedGoogle Scholar
• Busti AJ, Hooper JS, Amaya CJ, Kazi S. Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy. 2005;25(11):1566–1591.
   PubMed Web of Science ®Google Scholar
• Mooney DP, O'Reilly M, Gamelli RL. Tumor necrosis factor and wound healing. Ann Surg. 1990;211:124–129.
   PubMed Web of Science ®Google Scholar
• Lee, R, Efron DT, Udaya T, Stuelten C, Moldawer LL, Abouhamze A, Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound Repair Regen. 2000;8:547–553.
   PubMed Web of Science ®Google Scholar
• Rapala KT, Vaha-Kreula MO, Heino JJ, Vuorio EI, Laato MK. Tumor necrosis factor-alpha inhibits collagen synthesis in human and rat granulation tissue fibroblasts. Experientia. 1996;52(1):70–74.
   PubMedGoogle Scholar
• Salomon GD, Kasid A, Cromack DT, Director E, Talbot TL, Sank A, The local effects of cachectin.tumor necrosis factor on wound healing. Ann Surg. 1991;214(2):175–180.
   PubMed Web of Science ®Google Scholar
• Cowin AJ, Hatzirodos N, Rigden J, Fitridge R, Belford DA. Etanercept decreases tumor necrosis factor-alpha activity in chronic wound fluid. Wound Repair Regen. 2006;14:421–426.
   PubMed Web of Science ®Google Scholar
• Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic-Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16:585–601.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2008;58(5):826–850.
   PubMed Web of Science ®Google Scholar
• Enbrel (etanercept) for subcutaneous injection [monograph on internet]. Thousand Oaks, CA: Immunex Corp.; c. 2006 [accessed 2009 Sep 10]. Available from: http://www.enbrel.com/pdf/enbrel_pi.pdf.
   Google Scholar
• Humira (adalimumab) [monograph on internet]. North Chicago, IL: Abbott Laboratories; 2007 Jul [accessed 2009 Sep 10]. Available from: http://www.rxabbott.com/pdf/humira.pdf.
   Google Scholar
• Infliximab package insert [monograph on internet] [accessed 2009 Sep 10]. Available from: http://www.remicade.com/remicade/assets/HCP_PPI.pdf.
   Google Scholar
• Simponi (golimumab): product insert (US) [monograph on internet]. Centocor Ortho Biotech, Inc. [accessed 2009 Sep 10]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009125289s0001bl.pdf.
   Google Scholar
• European Medicine Agency (EMEA). Summary of product characteristics: Enbrel [accessed 10 Sep 2009]. Available from: http://www.emea.europa.eu.
   Google Scholar
• Gottlieb AB, Leonardi CL, Goffe BS, Ortonne JP, van der Kerkhof PC, Zitnik R, Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database. J Am Acad Dermatol. 2006;54(3 suppl 2):S92–S100.
   Web of Science ®Google Scholar
• Patel T, Gordon KB. Adalimumab: Efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther. 2004;17:427–431.
   PubMedGoogle Scholar
• Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, Adalimumab therapy for moderate-to-severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–115.
   PubMed Web of Science ®Google Scholar
• Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1–e15.
   Web of Science ®Google Scholar
• Gordon K, Tyring S, Gu Y, Okum M. Psoriasis patients treated continuously with adalimumab: Efficacy and safety results from months 12 to 18 [abstract]. J Am Acad Dermatol. 2008;58(2):AB129.
   Web of Science ®Google Scholar
• Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48:319–324.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis. 2005;41(suppl):S194–S198.
   Google Scholar
• Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Tuberculosis associated with infliximab, a tumor necrosis alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–1104.
   PubMed Web of Science ®Google Scholar
• Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565–2570.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade. Mayo Clin Proc. 2008;83:181–194.
   PubMed Web of Science ®Google Scholar
• Fleischman R, Iqbai I, Nandeshwar P, Quniceno A. Safety and efficacy of modifying anti-rheumatic agents: Focus on the benefits and risk of etanercept. Drug Safety. 2002;25:173–197.
   PubMed Web of Science ®Google Scholar
• Gisondi PG. Biologic therapies in psoriasis: A new therapeutic approach. Autoimmun Rev. 2007;6(8):515–519.
   PubMed Web of Science ®Google Scholar
• Darabi K, Jaiswal R, Hostetler S, Bechtel M, Zirwas M. Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate. J Drugs Dermatol. 2009;8(2):175–178.
   PubMed Web of Science ®Google Scholar
• Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Infliximab for severe, treatment-resistant psoriasis: A prospective, open-label study. Br J Dermatol. 2006;155(1):160–169.
   PubMed Web of Science ®Google Scholar
• Torralba KD, Quismorio FP. Soft tissue infections. Rheum Dis Clin North Am. 2009;35(1):45–62.
   PubMed Web of Science ®Google Scholar
• Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001;76:653–656.
   PubMed Web of Science ®Google Scholar
• Sangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. J Am Med Assoc. 2009;301(7):737–744.
   Web of Science ®Google Scholar
• Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, The risk of herpes zoster in patients with rheumatoid arthritis in the United States and United Kingdom. Arthritis Rheum. 2007;57(8):1431–1438.
   PubMedGoogle Scholar
• Dixon WG, Watson K, Lunt M, Hyrich KL. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006;54(8):2368–2376.
   PubMedGoogle Scholar
• Esposito S. Immune system and surgical site infection. J Chemother. 2001;1(1):12–16.
   Google Scholar
• Topstad DR, Panaccione R, Heine JA, Johnson DRE, MacLean AR, Buie WD. Combined seton placement, infliximab infusion and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease. Dis Colon Rectum. 2003;46:577–583.
   PubMed Web of Science ®Google Scholar
• Gaertner WB, Decanini A, Mellgren A, Lowry A, Goldberg SM, Madoff RD, Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum. 2007;50(11):1735–2012.
   PubMed Web of Science ®Google Scholar
• Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg. 2008;12:1730–1737.
   PubMed Web of Science ®Google Scholar
• Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, The risk of post-operative complications associated with infliximab therapy for Crohn's disease: A controlled cohort study. Aliment Pharmacol Ther. 2004;19:749–754.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99:878–883.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119–133.
   PubMed Web of Science ®Google Scholar
• Schluender S, Ippoliti A, Dubinsky M, Vasiliauskas EA, Papadakis KA, Mei L, Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007;50:1747–1753.
   PubMed Web of Science ®Google Scholar
• Selvasekar C, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204(5):956–962.
   PubMed Web of Science ®Google Scholar
• Bongartz T. Elective orthopedic surgery and perioperative DMARD management: Many questions, fewer answers, and some opinions. J Rheumatol. 2007;34(4):653–655.
   PubMed Web of Science ®Google Scholar
• Talwalkar SC, Grennan DM, Gray J, Johnson P, Hayton MJ. Tumor necrosis factor antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis. 2005;64(4):650–651.
   PubMed Web of Science ®Google Scholar
• Wendling D, Balblanc J-C, Brousse A, Lohse A, Lehuede G, Garbuio P, Surgery in patients receiving anti-tumour necrosis factor α treatment in rheumatoid arthritis: An observational study on 50 surgical procedures. Ann Rheum Dis. 2005;64:1378–1379.
   PubMed Web of Science ®Google Scholar
• Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-α inhibition therapy. Foot Ankle Int. 2004;25:331–335.
   PubMed Web of Science ®Google Scholar
• den Broeder AA. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: A large retrospective study. J Rheumatol. 2007;34(4):689–695.
   PubMed Web of Science ®Google Scholar
• Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum. 2002;46(9):2287–2293.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59(12):1713–1720.
   PubMed Web of Science ®Google Scholar
• Hamalainen M, Raunio P, Von Essen R. Postoperative wound infection in rheumatoid arthritis surgery. Clin Rheumatol. 1984;3:329–335.
   PubMed Web of Science ®Google Scholar
• Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Ann Rheum Dis. 2001;60:214–217.
   PubMed Web of Science ®Google Scholar
• Hernandez C, Emer J, Robinson JK. Perioperative management of medications for psoriasis and psoriatic arthritis: A review for the dermasurgeon. Dermatol Surg. 2008;34:446–459.
   PubMed Web of Science ®Google Scholar
• Saini R, Shupack JL. Psoriasis: To cut or not to cut, what say you? Dermatol Surg. 2003;29:735–740.
   PubMed Web of Science ®Google Scholar
• Lynfield YL, Ostroff G, Abraham J. Bacteria, skin sterilization, and wound healing in psoriasis. N Y State J Med. 1972;72:1247–1250.
   PubMedGoogle Scholar
• Noble WC, Savin JA. Carriage of Staphylococcus aureus in psoriasis. Br Med J. 1968;(i):417–418.
   PubMedGoogle Scholar
• Lambert JR, Wright V. Surgery in patients with psoriasis and arthritis. Rheumatol Rehabil. 1979;18:35–37.
   PubMedGoogle Scholar
• Beyer CA, Hanssen AD, Lewallen DG, Pittelkow MR. Primary total knee arthroplasty in patients with psoriasis. J Bone Joint Surg. 1991;73:258–259.
   Web of Science ®Google Scholar
• Hicken GJ, Kitaoka HB, Valente RM. Foot and ankle surgery in patients with psoriasis. Clin Orthop. 1994;300:201–206.
   Google Scholar
• Stern SH, Insall JN, Windsor RE, Inglus AE, Dines DM. Total knee arthroplasty in patients with psoriasis. Clin Orthop Relat Res. 1989;248:108–111.
   PubMed Web of Science ®Google Scholar
• Menon TJ, Wroblenski BM. Charnley low friction arthroplasty in patients with psoriasis. Clin Orthop Relat Res. 1983;176:127–128.
   Google Scholar
• Cheleuitte E, Fleischli J, Tisa L, Zombolo R. Psoriasis and elective foot surgery. J Foot Ankle Surg. 1996;35:297–302.
   PubMedGoogle Scholar
• Lima XT, Seidler EM, Lima HC, Kimball AB. Long-term safety of biologics in dermatology. Dermatol Ther. 2009;22:2–21.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Roxel AB. Risk of myocardial infarction in patients with psoriasis. J Am Med Assoc. 2006;296:1735–1741.
   PubMed Web of Science ®Google Scholar
• Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: A case–control study. J Am Acad Dermatol. 2007;56(4):629–634.
   PubMed Web of Science ®Google Scholar
• Neimann AL, Shin DB, Wang X, Margolis DJ, Roxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829–835.
   PubMed Web of Science ®Google Scholar
• Pieringer H, Stuby U, Biesenbach G. Patients with rheumatoid arthritis undergoing surgery: How should we deal with antirheumatic treatment? Semin Arthritis Rheum. 2007;36:278–286.
   PubMed Web of Science ®Google Scholar
• Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia A, A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56(4):598–603.
   PubMed Web of Science ®Google Scholar
• Rosandich PA, Kelley JT, Conn DL. Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers. Curr Opin Rheumatol. 2004;16:192–198.
   PubMed Web of Science ®Google Scholar